IV Ceftriaxone to Keflex Dosage Conversion
For most adult patients transitioning from IV ceftriaxone to oral cephalexin (Keflex), use cephalexin 500 mg orally every 6 hours (four times daily) for skin and soft tissue infections. This dosing is directly supported by IDSA guidelines for surgical site infections of the trunk or extremity 1.
Adult Dosing Recommendations
Standard Conversion for Skin/Soft Tissue Infections
- Cephalexin 500 mg orally every 6 hours is the guideline-recommended dose for trunk/extremity infections 1
- This provides equivalent coverage to ceftriaxone 1-2 grams IV daily for susceptible organisms
- Continue for the same total duration as planned for IV therapy (typically 7-14 days for most infections)
Alternative Dosing Considerations
Recent evidence suggests cephalexin 500 mg twice daily may be non-inferior for uncomplicated mild-moderate skin and soft tissue infections 2. However, this simplified regimen should be reserved for:
- Uncomplicated, mild-moderate infections only
- Patients with demonstrated clinical improvement on IV therapy
- When adherence concerns outweigh the need for more frequent dosing
For serious infections or those requiring more aggressive therapy, maintain the four-times-daily dosing to ensure adequate drug exposure throughout the dosing interval.
Pediatric Dosing
For children transitioning from ceftriaxone 50-75 mg/kg/day:
- Cephalexin 25 mg/kg/dose (maximum 750 mg) three times daily achieves appropriate pharmacodynamic targets 3, 4
- Alternative: 45 mg/kg/dose (maximum 1.5 g) three times daily for bone/joint infections, which is effective and well-tolerated 4
- The three-times-daily regimen improves adherence compared to traditional four-times-daily dosing
Critical Caveats
When NOT to Use Cephalexin
- Infections involving the axilla or perineum: These require broader coverage (e.g., ceftriaxone + metronidazole) due to polymicrobial/anaerobic involvement 1
- Suspected MRSA: Cephalexin has no activity against methicillin-resistant organisms; consider alternative agents
- Severe/complicated infections: May require continued IV therapy or alternative oral agents with better bioavailability
Monitoring Requirements
- Assess clinical response at 48-72 hours after transition
- Treatment failure rates are generally low (4-6%) with appropriate dosing 2
- If symptoms worsen or fail to improve, consider:
- Resistant organisms (including MRSA)
- Inadequate source control
- Alternative diagnosis
Drug-Specific Considerations
The FDA label for ceftriaxone indicates typical adult dosing of 1-2 grams daily 5, with excellent tissue penetration. Cephalexin, while having lower bioavailability, achieves adequate tissue concentrations when dosed appropriately at 500 mg every 6 hours for serious infections 1.
Avoid cefdinir as an alternative - recent data shows nearly twice the failure rate compared to cephalexin for urinary infections, with higher rates of subsequent cephalosporin resistance 6, 7.